Бастиан Блоэм - Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний

58. Langston JW. The MPTP story. Journal of Parkinsons Disease. 2017;7(s1):S11-S19.

59. “NOVA; case of the frozen addict, the.” OpenVault from WGBH Boston/ BBC TV. February 18, 1986. http://openvault.wgbh.org/catalog/V_474C F2C8A20B4173988486AC4C605A3C. At 00:55:25.

60. Meredith GE, Rademacher DJ. MPTP mouse models of Parkinson’s disease: an update. Journal of Parkinson’s Disease. 2011;1(1):19–33; Porras G, Li Q, Bezard E. Modeling Parkinson’s disease in primates: the MPTP model. Cold Spring Harbor Perspectives in Medicine . 2012;2(3):a009308.

61. Cornelius CE. Animal models – a neglected medical resource. New England Journal of Medicine. 1969;281(17):934–944; Overall KL. Natural animal models of human psychiatric conditions: assessment of mechanism and validity. Progress in Neuro-psychopharmacology and Biological Psychiatry . 2000;24(5):727–776.

62. Barre-Sinoussi F, Montagutelli X. Animal models are essential to biological research: issues and perspectives. Future Science OA . 2015;1(4):FSO63-FSO63.

63. Там же.

64. Giasson BI, Lee VMY. A new link between pesticides and Parkinson’s disease. Nature Neuroscience. 2000;3:1227–1228.

65. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nature Neuroscience. 2000;3(12):1301–1306.

66. Giasson BI, Lee VMY. A new link between pesticides and Parkinson’s disease. Nature Neuroscience. 2000;3:1227–1228.

67. Tanner CM, Kamel F, Ross GW, et al. Rotenone, paraquat, and Parkinson’s disease. Environmental Health Perspectives. 2011;119(6):866–872.

68. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the a-synuclein gene identified in families with Parkinson’s disease. Science. 1997;276(5321):2045–2047.

69. Olanow CW, Brundin P. Parkinson’s disease and alpha synuclein: is Parkinson’s disease a prion-like disorder? Movement Disorders. 2013;28(1):31–40; Uversky VN, Li J, Fink AL. Pesticides directly accelerate the rate of a-synuclein fibril formation: a possible factor in Parkinson’s disease. FEBS Letters. 2001;500(3):105–108.

70. Luk KC, Kehm V, Carroll J, et al. Pathological a-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science . 2012;338(6109):949–953.

71. Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nature Reviews Neurology. 2013;9(1):13–24.

72. Spillantini MG, Schmidt ML, Lee VMY, Trojanowski JQ, Jakes R, Goedert M. a-synuclein in Lewy bodies. Nature. 1997;388:839–840; Mezey E, Dehejia AM, Harta G, et al. Alpha synuclein is present in Lewy bodies in sporadic Parkinson’s disease. Molecular Psychiatry . 1998;3:493–499.

73. Holdorff B. Friedrich Heinrich Lewy (1885–1950) and his work. Journal of the History of the Neurosciences. 2002;11(1):19–28.

74. Brin S. LRRK2. Too . September 18, 2008. http://too.blogspot. com/2008/09/lrrk2.html.

75. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44(4):601–607.

76. Там же.; Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common LRRK2 mutation in idiopathic Parkinson’s disease. The Lancet. 2005;365(9457):415–416; Di Fonzo A, Roh6 CF, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson’s disease. The Lancet. 2005;365(9457):412–415.

77. Brin S. LRRK2. Too . September 18, 2008. http://too.blogspot. com/2008/09/lrrk2.html.

78. Там же.

79. Sergey Brin. Inside Philanthropy. www.insidephilanthropy.com/guide-to-individual-donors/sergey-brin.html. Accessed March 20, 2019; Goetz T. Sergey Brin’s search for a Parkinson’s cure. Wired. January 22, 2010. www.wired.com/2010/06/ff-sergeys-search. Accessed June 28, 2019.

80. The Associated Press. Twins study links Parkinson’s disease to the environment. New York Times. February 2, 1999.

81. Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harbor Perspectives in Medicine. 2012;2(1):a008888; Fleming SM. Mechanisms of gene-environment interactions in Parkinson’s disease. Current Environmental Health Reports. 2017;4(2):192–199.

82. Klein C, Westenberger A. Genetics of Parkinson’s disease. Cold Spring Harbor Perspectives in Medicine. 2012;2(1):a008888.

83. Fleming SM. Mechanisms of gene-environment interactions in Parkinson’s disease. Current Environmental Health Reports . 2017;4(2):192–199.

84. www.reuters.com/article/us-cancer-lung-nutrients-sb/nutrients-may-be-why-some-smokers-avoid-cancer-idUSTRE65E5JW20100616.

85. www.nature.com/articles/nature06846;www.nature.com/articles/ng.3892.

86. www.ncbi.nlm.nih.gov/pmc/articles/PMC4501942; https://pubmed. ncbi.nlm.nih.gov/ 28639421-penetrance-estimate-of-lrrk2-pg2019s-mutation-in-individuals-of-non-ashkenazi-jewish-ancestry.

87. Ryan SD, Dolatabadi N, Chan SF, et al. Isogenic human iPSC Parkinson’s model shows nitrosative stress-induced dysfunction in MEF2-PGC1 atranscription. Cell . 2013;155(6):1351–1364.

88. Nuber S, Tadros D, Fields J, et al. Environmental neurotoxic challenge of conditional alpha-synuclein transgenic mice predicts a dopaminergic olfactorystriatal interplay in early PD. Acta Neuropathologica . 2014;127(4):477–494.

89. Liu H-F, Ho PW-L, Leung GC-T, et al. Combined LRRK2 mutation, aging and chronic low dose oral rotenone as a model of Parkinson’s disease. Scientific Reports. 2017;7:40887. doi:10.1038/srep40887.

90. Weiner WJ. There is no Parkinson disease. Archives of Neurology. 2008;65(6):705–708.

91. Malek N, Weil RS, Bresner C, et al. Features of GBA-associated Parkinson’s disease at presentation in the UK Tracking Parkinson’s study. Journal of Neurology, Neurosurgery & Psychiatry. 2018;89(7):702–709; Saunders-Pullman R, Mirelman A, Alcalay RN, et al. Progression in the LRRK2– associated Parkinson disease population. JAMA Neurology. 2018;75(3):312–319.

92. Parkinson J. An essay on the shaking palsy. Journal of Neuropsychiatry and Clinical Neurosciences. 2002;14(2):223–236.

93. Braak H, Del Tredici K, Rub U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiology of Aging. 2003;24(2):197–211; Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. Journal of Neural Transmission. 2003;110(5):517–536.

94. Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. Journal of Neural Transmission . 2003;110(5):517–536.

95. Silva BA, Einarsdottir O, Fink AL, Uversky VN. Biophysical characterization of a-synuclein and rotenone interaction. Biomolecules. 2013;3(3):703–732.

96. Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta Neuropathologica. 2010;119(6):703–713; Del Tredici K, Braak H. Spinal cord lesions in sporadic Parkinson’s disease. Acta Neuropathologica . 2012;124(5):643–664.

97. Breen DP, Halliday GM, Lang AE. Gut-brain axis and the spread of a-synuclein pathology: vagal highway or dead end? Movement Disorders . 2019;34(3):307–316.